IPM Take
This is not only a new bladder-cancer approval. It is a demand for a better surgical-oncology pathway. A regimen that starts before cystectomy and continues after surgery requires tight coordination between urology, medical oncology, pathology, nursing, toxicity management and patient navigation. If the system is slow, fragmented or under-resourced, the approval will reach paper before it reaches patients.
Executive Summary
The FDA approved pembrolizumab or subcutaneous pembrolizumab and berahyaluronidase alfa-pmph, each in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer who are candidates for surgery. The decision expands the prior approval from cisplatin-ineligible patients to all cystectomy-eligible adults with MIBC. In KEYNOTE-B15/EV-304, the combination significantly improved event-free survival and overall survival versus neoadjuvant gemcitabine and cisplatin followed by surgery. Median event-free survival was not reached in the pembrolizumab/enfortumab vedotin arm versus 48.5 months in the chemotherapy arm, with a hazard ratio of 0.53. Overall survival was also improved, with a hazard ratio of 0.65.
Why it matters
- Patients / advocates: This may widen access to perioperative immunotherapy–ADC treatment beyond the old cisplatin eligibility divide.
- Clinicians: Treatment is no longer a single pre-surgery decision. It becomes a full perioperative strategy.
- Hospitals / providers: Cystectomy pathways must manage scheduling, toxicity, surgery timing, post-operative recovery and adjuvant continuation.
- Payers / public authorities: A longer treatment sequence means higher system cost and a stronger need for real-world outcomes tracking.
The centre of gravity in muscle-invasive bladder cancer has moved.
For years, one of the sharpest dividing lines in this disease was cisplatin eligibility. Patients who could tolerate cisplatin-based chemotherapy had one kind of pathway. Those who could not had another. The FDA’s 10 July approval of pembrolizumab plus enfortumab vedotin before and after cystectomy pushes the field into a broader perioperative model.
The clinical signal is strong. In KEYNOTE-B15/EV-304, the pembrolizumab/enfortumab vedotin strategy significantly improved both event-free survival and overall survival compared with gemcitabine and cisplatin followed by surgery. The FDA reports a hazard ratio of 0.53 for event-free survival and 0.65 for overall survival. That is not an administrative label change. It is a challenge to the current treatment architecture.
But this kind of progress is not plug-and-play.
A patient has to be diagnosed, staged, referred, assessed for surgery, started on neoadjuvant treatment, monitored for toxicity, protected from delays, taken through cystectomy, recovered, and then considered for adjuvant therapy. Every weak point in that chain can turn a regulatory approval into a missed opportunity.
The safety burden is also not trivial. The FDA notes that pembrolizumab carries warnings for immune-mediated adverse reactions and infusion-related reactions, while enfortumab vedotin includes warnings for skin reactions, hyperglycaemia, pneumonitis or interstitial lung disease, peripheral neuropathy and ocular disorders.
That means implementation cannot be reduced to “add the regimen.” It requires teams that can recognise and manage toxicity without derailing surgery. It requires scheduling discipline. It requires patient navigation. It requires centres to know whether they can deliver the full pathway safely, not just the first dose.
This is exactly the kind of approval that separates high-performing cancer systems from systems that only look modern on paper.
